Skip to main content
. 2003 Oct 15;31(20):5817–5830. doi: 10.1093/nar/gkg801

Figure 6.

Figure 6

Figure 6

Figure 6

‘Hybrid’ CpG PTO–LNA ODNs bind to plasmid and retain CpG activity in vitro. (A) Agarose gel (without EtBr) of 0.027 µM plasmid pGG2XEMPTY incubated with ODNs, labelled either by Ulysis Alexa Fluor 488 or by Alexa Fluor 568 at the 5′ end. (B) As (A) with EtBr. Lane M, 1 kb DNA ladder; lane 1, pGG2xEMPTY; lane 2, pGG2xEMPTY + 4 µM 5′ Alexa Fluor 568-labelled LNA8; lane 3, pGG2xEMPTY + 4 µM Ulysis-labelled LNA8; lane 4, pGG2xEMPTY + 9 µM Ulysis-labelled PTOCpG-LNA; lane 5, pGG2xEMPTY + 9 µM Ulysis-labelled PTOGpC-LNA. (C) Agarose gel (without EtBr) of plasmid incubated with Ulysis-labelled ‘hybrid’ PTO–LNA ODNs before and after S400HR gel exclusion chromatography. (D) As (C) with EtBr. Lane M, 1 kb DNA ladder; 0.027 µM pGG2xEMPTY + 9 µM PTOCpG-LNA before (lane 1) and after S400HR separation (lane 2). (E) TNF-α ELISA data for the dose response curve of gWiz plasmid ± bound PTOCpG–LNA or PTOGpC–LNA, transfected into RAW264.7.